| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 09/04/2003 | US20030165485 Functional role and potential therapeutic use of Reelin, Gas6 and Protein S in relation to adult neural stem or progenitor cells |
| 09/04/2003 | US20030165482 Skin disorders; wound healing agents; antiscarring agents |
| 09/04/2003 | US20030165481 Amyloid peptide inactivating enzyme to treat Alzheimer's disease |
| 09/04/2003 | US20030165478 Stabilized synthetic immunogen delivery system |
| 09/04/2003 | US20030165477 Poxvirus with targeted infection specificity |
| 09/04/2003 | US20030165469 Construction of high efficiency retroviral vector for gene therapy of hunter syndrome |
| 09/04/2003 | US20030165467 Angiogenic factor and use thereof in treating cardiovascular disease |
| 09/04/2003 | US20030165466 Recombinant poliovirus for the treatment of cancer |
| 09/04/2003 | US20030165464 In vivo stimulation of angiogenic activity |
| 09/04/2003 | US20030165463 Enhanced system for construction of adenovirus vectors |
| 09/04/2003 | US20030165462 Deleted adenovirus vectors and methods of making and administering the same |
| 09/04/2003 | US20030165434 Delivery of polynucleotide agents to the central nervous system |
| 09/04/2003 | CA2477283A1 Vascular therapeutic methods and compositions involving the reduction or prevention of c-jun mediated processes |
| 09/04/2003 | CA2477281A1 Method of using modified oligonucleotides for hepatic delivery |
| 09/04/2003 | CA2477037A1 Recombinant negative strand virus rna expression systems and vaccines |
| 09/04/2003 | CA2476994A1 Methods of extending corneal graft survival |
| 09/04/2003 | CA2476887A1 Gasp1:a follistatin domain containing protein |
| 09/04/2003 | CA2476769A1 Carbohydrate-modified polymers, compositions and uses related thereto |
| 09/04/2003 | CA2476480A1 Methods of making hypermutable cells using pmsr homologs |
| 09/04/2003 | CA2475433A1 Trpm-2 antisense therapy using an oligonucleotide having 2'-o-(2-methoxyl)ethyl modifications |
| 09/04/2003 | CA2474751A1 Expression system for human brain-specific voltage-gated sodium channel, type 1 |
| 09/04/2003 | CA2467833A1 Pharmaceutical compositions in particulate form |
| 09/04/2003 | CA2451982A1 Method and nucleic acids for the analysis of colorectal cell proliferative disorders |
| 09/03/2003 | EP1340821A2 Method of detecting a variant of gh1 as indicator of growth hormone dysfunction |
| 09/03/2003 | EP1340820A2 Method of detecting a variant of gh1 as indicator of growth hormone dysfunction |
| 09/03/2003 | EP1340818A1 Method and nucleic acids for the analysis of a colon cell proliferative disorder |
| 09/03/2003 | EP1340765A2 Inverted chimeric and hybrid oligonucleotides |
| 09/03/2003 | EP1340507A1 Use of fibroblast growth factor-binding protein for the treatment and diagnosis of diabetic wound healing |
| 09/03/2003 | EP1340505A2 Therapeutic use of cis-element decoys in vivo |
| 09/03/2003 | EP1339862A1 Photochemical internalization for virus-mediated molecule delivery into the cyosol |
| 09/03/2003 | EP1339847A2 Transforming growth factor-beta-related molecules and uses thereof |
| 09/03/2003 | EP1339753A2 Percarboxylated polysaccharides, and a process for their preparation |
| 09/03/2003 | EP1339738A2 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 09/03/2003 | EP1339737A2 Immunomodulatory protein derived from the yaba monkey tumor virus |
| 09/03/2003 | EP1339440A1 An implantable or insertable therapeutic agent delivery device |
| 09/03/2003 | EP1339433A2 Expression of keratin genes 8 and 18 for treating tumours, in particular a mammary carcinoma |
| 09/03/2003 | EP1086246A4 Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| 09/03/2003 | EP0857210B1 Therapeutic antiangiogenic compositions and methods |
| 09/03/2003 | EP0763116B1 Recombinant viruses, preparation and use thereof in gene therapy |
| 09/02/2003 | US6613957 Synthesis of functional human hemoglobin and other proteins in erythroid tissues of transgenic non-human mammals |
| 09/02/2003 | US6613956 Transgenic fly comprising a polynucleotide sequence under regulatory control of an eye specific promoter; phenotypic change in eye; can use for reducing cell death after trauma and treatment of cancer and diabetes |
| 09/02/2003 | US6613892 Continuously expressing an inserted heterologous gene while remaining latent |
| 09/02/2003 | US6613881 Isolated polypeptide of given amino acid sequence; can use in vaccines |
| 09/02/2003 | US6613787 Compounds that exhibit specific molecular recognition of mixed nucleic acid sequences and bind in the DNA minor groove as a dimer |
| 09/02/2003 | US6613751 Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
| 09/02/2003 | US6613750 Inhibiting growth of a tumor cell by introducing to the cell an effective amount of p19ARF protein or mimetic thereof, and p53 |
| 09/02/2003 | US6613749 Papovavirus pseudocapsids and use thereof for exogenous material transfer |
| 09/02/2003 | US6613735 Using quaternary ammonium compound |
| 09/02/2003 | US6613567 Antisense inhibition of Her-2 expression |
| 09/02/2003 | US6613563 Viral vectors with modified tropism |
| 09/02/2003 | US6613544 Osteoprotegerin |
| 09/02/2003 | US6613514 Evolving preferential protein; digest nuclelotide sequences substrate, join terminals, screen for preferential proteins, recover nucleotide sequences |
| 09/02/2003 | US6613351 Vector including a complex between at least one compound having an amidine polar head of formula where m is 14 and at least one of nucleic acids molecules, polypeptides, glycosylated polypeptides and membrane |
| 09/02/2003 | US6613322 Administering enzyme inhibitors |
| 09/02/2003 | US6613320 Recombinant CD4+ T cells from an individual afflicted with hyper IgM syndrome transformed with vectors carrying either the wild type or the mutagenized CD40Ls, metabolically radiolabeled, and examined for expression |
| 09/02/2003 | US6613319 Long-term expression of erythropoietin and growth hormone by transforming muscle cells |
| 08/28/2003 | WO2003070970A2 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA) |
| 08/28/2003 | WO2003070969A2 RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 08/28/2003 | WO2003070968A2 RNA INTERFERENCE MEDIATED INHIBITION OF GASTRIC INHIBITORY POLYPEPTIDE (GIP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 08/28/2003 | WO2003070958A1 Retroviral gene therapy vectors including insulator elements to provide high levels of gene expression |
| 08/28/2003 | WO2003070941A2 Method for the identification of tissue-specific regulatory sequences |
| 08/28/2003 | WO2003070923A1 Agent for inducing or inhibiting an angiogenesis |
| 08/28/2003 | WO2003070918A2 Rna interference by modified short interfering nucleic acid |
| 08/28/2003 | WO2003070914A2 RNA INTERFERENCE MEDIATED INHIBITION OF FOS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 08/28/2003 | WO2003070911A2 Rna interference mediated inhibition of type 1 insulin-like growth factor receptor (igf-1r) |
| 08/28/2003 | WO2003070910A2 INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 08/28/2003 | WO2003070906A2 Cellular genes regulated by hiv-1 infection and methods of use thereof |
| 08/28/2003 | WO2003070905A2 Electroporation methods for introducing bioactive agents into cells |
| 08/28/2003 | WO2003070903A2 RNA INTERFERENCE MEDIATED INHIBITION OF GRB2-ASSOCIATED BINDING PROTEIN 2 (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 08/28/2003 | WO2003070897A2 RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR SUPERFAMILY GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 08/28/2003 | WO2003070895A2 RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 08/28/2003 | WO2003070886A2 Inhibition of protein tyrosine phosphatase type iva expression byshort interfering nucleic acid |
| 08/28/2003 | WO2003070883A2 Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules. |
| 08/28/2003 | WO2003070881A2 RNA INTERFERENCE MEDIATED INHIBITION OF PROTEIN TYPROSINE PHOSPHATASE-1B (PTP-1B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 08/28/2003 | WO2003070771A1 Rrp sequences and knockout mice and uses thereof |
| 08/28/2003 | WO2003070768A2 Cd40 splice variants,method of detection thereof, compositions comprising said variant(s) or nucleic acid encoding the same and use thereof |
| 08/28/2003 | WO2003070767A1 Tissue specific expression |
| 08/28/2003 | WO2003070750A2 Rna interference mediated inhibition of hepatitis c virus |
| 08/28/2003 | WO2003070747A2 Insulin and igf-1 receptor agonists and antagonists |
| 08/28/2003 | WO2003070744A1 RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 08/28/2003 | WO2003070691A1 N-hydroxycarboxamide derivative |
| 08/28/2003 | WO2003070283A2 Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent |
| 08/28/2003 | WO2003070275A1 Use of an inhibitor or antagonist against tissue factor |
| 08/28/2003 | WO2003070271A2 Novel complexes for inducing an immune response |
| 08/28/2003 | WO2003070268A1 Remedy for infections |
| 08/28/2003 | WO2003070256A1 Hyaluronic acid mediated adenoviral transduction |
| 08/28/2003 | WO2003070221A1 Chemosensitizing with liposomes containing oligonucleotides |
| 08/28/2003 | WO2003070220A1 Ph-sensitive cationic lipids, and liposomes and nanocapsules containing the same |
| 08/28/2003 | WO2003070189A2 Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein |
| 08/28/2003 | WO2003062273A3 Modulator of the notch signalling pathway and use thereof in medical treatment |
| 08/28/2003 | WO2003060121A3 Compositions and methods relating to gastric specific genes and proteins |
| 08/28/2003 | WO2003029289A3 Fragements of heat shock proteins and their use |
| 08/28/2003 | WO2003025183A3 Random integration of a polynucleotide after in vivo linearization |
| 08/28/2003 | WO2003020894A3 Insulin related transcription factor and uses thereof |
| 08/28/2003 | WO2003016522A3 Methods and compounds for the targeting of protein to exosomes |
| 08/28/2003 | WO2003014153A3 Cellular virus receptors and methods of use. |
| 08/28/2003 | WO2002102990A3 Fibroblast growth factor and nucleic acid encoding same |
| 08/28/2003 | WO2002097044A3 Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| 08/28/2003 | WO2002088345A3 Murine dnasex, medicament containing the same and non-human mammal comprising modified dnasex gene |
| 08/28/2003 | WO2002086093A9 Methods of using a hyaluronan receptor |